The T-cell immunotherapy pipeline is very strong with a total of 139 drug candidates. Pharma giant such as Novartis, Kite Pharmaceuticals, Juno Therapeutics, Inc. and Sorrent Therapeutics, Inc. are actively involved in development of these therapeutics. There are 16 drug candidates in Phase II stage of development, 36 in Phase I, and seven in Phase 0. Two drug candidates have been filed for Investigational New Drug (IND) application, and there are 78 drugs in Pre-clinical and Discovery stage.
http://finance.yahoo.com/news/global-t-cell-immunotherapy-pipeline-165600381.html
Global T-Cell Immunotherapy Pipeline Analysis 2016-2017: Pipeline is Very Strong with a Total of 139 Drug Candidates – Research and Markets